Project Grant R61AT013127
Award Date 7/20/26
Completion Date 6/30/29
Dollars Obligated $3.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Belmont, MA 02478, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded The McLean Hospital Corporation $468,368 on September 5, 2026, to investigate the relationship between gut microbiome composition, multisensory sensitivity, and pain experience in adolescent girls with primary dysmenorrhea under CFDA 93.279 (Drug Use and Addiction Research Programs). The project will evaluate how alterations in gut microbiome composition contribute to multisensory sensitivity—heightened sensitivity to...
- The National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $170,640 on April 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds development and feasibility testing of TOPMED (Toolkit for Optimal Pain Management in the Emergency Department), a mind-body intervention designed to reduce pain...
- The National Center for Complementary and Integrative Health awarded Regents of the University of Michigan $574,978 on August 7, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to conduct a multi-site feasibility study of CAN-COACH, a cannabis coaching intervention for chronic low back pain. CAN-COACH uses motivational interviewing to coach individuals on the use of commercially available cannabis products for pain management, focusing on...
- The National Institute of Mental Health awarded Massachusetts Institute of Technology $543,711 on August 20, 2026, under the Mental Health Research Grants program (CFDA 93.242, Assistance Listing R01MH145508) to investigate endocannabinoid-mediated inhibitory synaptic mechanisms of hippocampal plasticity using all-optical physiology. The research employs simultaneous patterned optogenetic stimulation and genetically targeted voltage imaging to track synaptic plasticity with millisecond and...
- The National Center for Complementary and Integrative Health awarded Massachusetts General Hospital (operating as The General Hospital Corporation) a Cooperative Agreement totaling $1,258,356 on August 5, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). Performance runs through July 31, 2027, with work performed in Boston, Massachusetts. The award funds the Toolkit for Optimal Recovery After Orthopedic Injury (TOR), a multi-site efficacy...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $1.130557 million on August 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a non-viral lipid nanoparticle-delivered gene therapy for acute pain treatment as an alternative to opioids. The project focuses on creating a focal-delivery, non-opioid therapeutic targeting postsurgical pain as the primary indication, with secondary applications to acute exacerbations...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $429,162 Project Grant (CFDA 93.395, Cancer Treatment Research program) effective August 1, 2025 through July 31, 2027 to conduct a prospective feasibility study exploring the neuroprotective potential of cannabidiol (CBD) in preventing oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. The research deliverables include: (1) evaluation of the feasibility and...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $211,680 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026. The recipient will conduct mixed-methods research characterizing hemp-derived alternative cannabinoid product use in natural settings. The project comprises two national, decentralized studies: an online survey and a six-month naturalistic ecological momentary assessment study. Research will assess alternative...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $708,190 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to conduct double-blind, placebo-controlled human laboratory studies examining the pharmacokinetic and pharmacodynamic effects of varying tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios in cannabis edibles. Research Aim 1 will evaluate how different THC:CBD ratios—including 1:0, 1:1, 1:5, 1:10, 1:30, and 0:1—affect THC...
- The National Center for Complementary and Integrative Health (NCCIH) awarded the University of Massachusetts Medical School a $297,373 cooperative agreement on August 17, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213). The award funds a Data Coordinating Center (U24) to provide statistical and data management leadership for a multi-center Phase 3 randomized controlled trial (ACUITY 2) examining whether acupuncture is superior to usual care for...